Other analysts have also issued reports about the company. JPMorgan Chase & Co. reaffirmed a buy rating and issued a $195.00 price objective on shares of bluebird bio in a research note on Thursday, June 13th. BMO Capital Markets dropped their target price on bluebird bio from $191.00 to $163.00 and set an outperform rating for the company in a research report on Monday, June 17th. William Blair downgraded bluebird bio from an outperform rating to a market perform rating in a research report on Monday, August 12th. Morgan Stanley dropped their target price on bluebird bio from $143.00 to $136.00 and set an equal weight rating for the company in a research report on Tuesday, August 6th. Finally, ValuEngine upgraded bluebird bio from a buy rating to a strong-buy rating in a research report on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating, ten have issued a buy rating and two have given a strong buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus price target of $154.13.
NASDAQ:BLUE opened at $106.81 on Tuesday. The stock’s 50-day simple moving average is $110.87 and its 200 day simple moving average is $130.42. The firm has a market capitalization of $5.94 billion, a PE ratio of -10.00 and a beta of 2.28. The company has a quick ratio of 8.02, a current ratio of 8.02 and a debt-to-equity ratio of 0.11. bluebird bio has a twelve month low of $87.49 and a twelve month high of $163.43.
In other news, insider Philip D. Gregory sold 850 shares of the firm’s stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $116.93, for a total transaction of $99,390.50. Following the completion of the transaction, the insider now directly owns 31,192 shares in the company, valued at $3,647,280.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Philip D. Gregory sold 950 shares of the firm’s stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $124.03, for a total value of $117,828.50. Following the transaction, the insider now owns 31,042 shares of the company’s stock, valued at $3,850,139.26. The disclosure for this sale can be found here. Insiders have sold 12,870 shares of company stock valued at $1,563,309 over the last 90 days. 3.00% of the stock is owned by corporate insiders.
Several institutional investors and hedge funds have recently modified their holdings of the company. Trust Co. of Vermont raised its position in shares of bluebird bio by 40.6% during the second quarter. Trust Co. of Vermont now owns 253 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 73 shares during the last quarter. LPL Financial LLC increased its holdings in bluebird bio by 1.6% in the second quarter. LPL Financial LLC now owns 5,373 shares of the biotechnology company’s stock worth $683,000 after purchasing an additional 84 shares in the last quarter. Capital Investment Advisory Services LLC increased its holdings in bluebird bio by 100.0% in the second quarter. Capital Investment Advisory Services LLC now owns 200 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 100 shares in the last quarter. First Light Asset Management LLC increased its holdings in bluebird bio by 0.5% in the second quarter. First Light Asset Management LLC now owns 18,840 shares of the biotechnology company’s stock worth $2,396,000 after purchasing an additional 103 shares in the last quarter. Finally, Clearbridge Investments LLC increased its holdings in bluebird bio by 18.2% in the first quarter. Clearbridge Investments LLC now owns 839 shares of the biotechnology company’s stock worth $132,000 after purchasing an additional 129 shares in the last quarter.
About bluebird bio
bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder.
Recommended Story: What Factors Can Affect Return on Equity?
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.